Evidence map›Paper›PMID 30792825›Full record

ArticleCurrent therapeutic research, clinical and experimental2018

Effectiveness and Tolerability of 3-Day Mebendazole Treatment of

Roberto Cañete, Katia Brito, Inara Brito, Abel Semper, Maria Elena Gonzalez

Open access · goldAbstract read
In one paragraph

Article in Current therapeutic research, clinical and experimental, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Roberto CañeteCouncil of Scientific Societies of Health, University of Medical Sciences, Matanzas City, Cuba.
Katia BritoCentre for Hygiene, Epidemiology, and Microbiology, Matanzas City, Cuba.
Inara BritoMinistry of Health, Regional Office, Matanzas City, Cuba.
Abel SemperUniversity of Medical Sciences, Matanzas City, Cuba.
Maria Elena GonzalezCuban Institute of Gastroenterology, Havana, Cuba.
University of Matanzas · CUInstituto de Gastroenterología · CU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background

objectiveThe 2 additional, prospective, open-label, Phase IV follow-up studies reported here were performed to further assess the effectiveness and safety profile of mebendazole in the outpatient treatment of

methodsAssenting children (n = 522) whose guardians gave permission and consenting adults (n = 423) diagnosed with

resultsNo participant refused to be enrolled and all returned for follow-up examinations. At the end of the treatment, stool samples were negative in 450 out of 522 children (86.2%) and 392 of 423 adults (92.7%). Treatment was well tolerated. In adults, the only adverse effect reported was abdominal pain (6.2%). Side effects reported in children included abdominal pain (5.6%), nausea (2.9%), and vomiting (2.3%). Reported side effects were all mild, transient, and self-limited and did not require discontinuation of treatment or additional

conclusionsMebendazole may be an effective alternative treatment of

Indexed as

clinical trialdrug therapyGiardia duodenalismebendazolePhase IV

Identifiers

PMID30792825
PMCPMC6370949
OpenAlexW2902221504

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.